BCLI:NSD-Brainstorm Cell Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.19

Change

+0.21 (+1.50)%

Market Cap

USD 0.46B

Volume

0.24M

Average Target Price

USD 20.00 (+40.94%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.69 (-0.26%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-7.73 (-1.37%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+0.16 (+0.09%)

USD31.19B N/A N/A
MRNA Moderna, Inc

-1.99 (-2.96%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-1.55 (-3.71%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

-0.41 (-0.36%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+1.89 (+0.69%)

USD24.64B N/A N/A
GMAB Genmab A/S

-1.06 (-2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.13 (+0.15%)

USD19.69B N/A N/A
INCY Incyte Corporation

-0.90 (-1.05%)

USD18.80B 47.64 35.20

ETFs Containing BCLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 231.54% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 231.54% 95% A 96% A
Trailing 12 Months  
Capital Gain 255.64% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 255.64% 92% A- 96% A
Trailing 5 Years  
Capital Gain 404.98% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 404.98% 94% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 37.01% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.01% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 64.57% N/A N/A N/A N/A
Risk Adjusted Return 57.31% N/A N/A N/A N/A
Market Capitalization 0.46B 63% D 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 46.93 1% F 1% F
Price / Cash Flow Ratio -41.15 90% A- 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,086.85% 3% F 1% F
Return on Invested Capital 638.30% 99% A+ 100% A+
Return on Assets -128.73% 2% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.20 30% F 18% F
Short Percent 13.48% 20% F 15% F
Beta 1.08 69% D+ 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.